Company Overview and News
KUALA LUMPUR (Aug 30): Selangor Dredging Bhd will shift its focus to the Singapore property market due to an oversupply in the Malaysian residential real estate segment.
KUALA LUMPUR: Kumpulan Perangsang Selangor Bhd (KPS), Selangor Dredging Bhd (SDB), UMW Holdings Bhd and TA Enterprise Bhd are among the stocks to watch on Tuesday, according to JF Apex Research.
4898 2224 5843 KMTUF 4588
KUALA LUMPUR: Selangor Dredging Bhd (SDB) has entered into an agreement to purchase, via Tiara Land Pte Ltd, 17 parcels of land from individual owners for a sum of S$60.3mil (RM180.05mil).
KUALA LUMPUR (July 3): The FBM KLCI is expected to trade range bound today within a tight band, in line with the lower overnight close at most global markets, but could find some encouragement from the positive close at Wall Street.
6912 2224 1155 5843 4588 MLYBY MLYNF 2208
KUALA LUMPUR (July 2): Based on corporate announcements and news flow today, companies in focus on Tuesday (July 3) may include: Maybank, Petaling Tin, KPS, UMW, Computer Forms, Parlo, Selangor Dredging, Pasdec, Tropicana and MyEG.
6912 2224 1155 5843 KMTUF 4588 MLYBY MLYNF 2208 8044
KUALA LUMPUR (July 2): Selangor Dredging Bhd (SDB) announced today its associate company plans to buy 17 parcels of adjacent properties in the prime District 13 in Singapore for S$60.26 million (RM180.06 million), where the latter intends to develop exclusive mid-rise apartments.
2224 BSMAF 1818
KUALA LUMPUR, July 2 — Selangor Dredging Berhad (SDB) has entered into an agreement to purchase via Tiara Land Pte Ltd, a 50 per cent-associated company of SDB International Sdn Bhd, 17 parcels of land from individual landowners for a sum of S$60,262,500, which is equivalent to RM180,048,768, a statement today said.
SLOWDOWN or not, there are still multi-million ringgit deals to be made and last year saw its fair share of real estate transactions of above RM10 million each. From residential high-end bungalows to prime development lands, from office buildings to heritage shophouses and factory units, there was definitely something for every buyer with deep pockets.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...